This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
STAMFORD, Conn., July 17, 2018 (GLOBE NEWSWIRE) -- Hexcel Corporation (NYSE:HXL) and Groupe Gazechim Composites, an official Hexcel distributor for more than 20 years, have reached agreement to provide customized kitting services for advanced composite materials sold to aerospace and defense customers and for high-performance industrial applications.
Stocks were looking for a very strong open on Thursday after the Independence Day holiday had U.S. markets closed on Wednesday. The prior trend of buying the dips has been less reliable during most of 2018 than in prior years. Many investors have been considering how they want their investments positioned ahead of the midterm elections and also for the longer term.
QRVO FB CQP GERN CYGMD LNG HXL WCG ACT CYGM VLRX AGN CLNE AGN.PRA HXL TRI BIP HRS NTAP FCAU INTC KOS
STAMFORD, Conn., July 03, 2018 (GLOBE NEWSWIRE) -- Hexcel Corporation (NYSE:HXL) announced today that it will report financial results for its second quarter of 2018 on Monday, July 23 after the market close.
SQ Advisors has just fifteen positions. The top three holdings are Allison Transmission, Brookfield Asset Management, and Charles Schwab, and they add up to one-third of the entire portfolio.
KMX LBTY HXL ALSN CAXPF TYLE CHTR LBTYK TYL LILAB AAPL BAM ST LBRDB SCHW.PRBCL CABO BAMGF BBU LBTYB AXTA LBTYA LBRDK BRK.A SCHW HXL LILAK LBRDA SBAC BAMKF LILA
* HEXCEL CORP - REPURCHASES WILL BE FUNDED FROM CASH FROM OPERATING ACTIVITIES AND, IF NEEDED, COMPANY’S EXISTING LOAN FACILITY Source text for Eikon: Further company coverage:
STAMFORD, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Hexcel Corporation (NYSE:HXL) announced today that the Company’s Board of Directors has authorized the repurchase of an additional $500 million of the Company’s stock.
Good day, ladies and gentlemen, and welcome to the Q1 2018 Hexcel Corporation Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
STAMFORD, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Hexcel Corporation (NYSE:HXL) today announced that the Company’s Board of Directors has declared a regular quarterly cash dividend of $0.125 per share on the common stock of Hexcel, payable on May 11, 2018 to stockholders of record as of May 4, 2018.
Raytheon Company’s (RTN - Free Report) Missile Systems business segment recently won a modification contract for production of Advanced Medium Range Air to Air Missile’s (AMRAAM) 31st Lot. Work related to the deal is scheduled to be over by Jan 31, 2021.
TDG HXL HXL RTN CW
16h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
17h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to EPA:HXL / HEXCEL on message board site Silicon Investor.